CXCL13 and Chronic Eosinophilic Leukemia, Not Otherwise Specified: This would suggest that IL-12p40 and CXCL13 do not participate in the events leading to BBB opening, which is supported by published observations that systemic administration of IL-12p40-targeting therapies does not abrogate development of CEL [61].